Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Development of a novel heart failure risk tool: the barcelona bio-heart failure risk calculator (BCN bio-HF calculator).

Lupón J, de Antonio M, Vila J, Peñafiel J, Galán A, Zamora E, Urrutia A, Bayes-Genis A.

PLoS One. 2014 Jan 15;9(1):e85466. doi: 10.1371/journal.pone.0085466. eCollection 2014.

2.

Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.

de Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A.

Am Heart J. 2012 May;163(5):821-8. doi: 10.1016/j.ahj.2012.03.004.

PMID:
22607860
3.

Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment.

Lupón J, de Antonio M, Galán A, Vila J, Zamora E, Urrutia A, Bayes-Genis A.

Mayo Clin Proc. 2013 Mar;88(3):234-43. doi: 10.1016/j.mayocp.2012.09.016. Epub 2013 Feb 4. Erratum in: Mayo Clin Proc. 2013 May;88(5):532.

PMID:
23384388
4.

Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.

Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, Zamora E, Urrutia A, Lupón J.

J Am Coll Cardiol. 2014 Jan 21;63(2):158-66. doi: 10.1016/j.jacc.2013.07.087. Epub 2013 Sep 24.

5.

Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure.

Bayes-Genis A, de Antonio M, Galán A, Sanz H, Urrutia A, Cabanes R, Cano L, González B, Díez C, Pascual T, Elosúa R, Lupón J.

Eur J Heart Fail. 2012 Jan;14(1):32-8. doi: 10.1093/eurjhf/hfr156.

6.

Head-to-head comparison of high-sensitivity troponin T and sensitive-contemporary troponin I regarding heart failure risk stratification.

de Antonio M, Lupón J, Galán A, Vila J, Zamora E, Urrutia A, Díez C, Coll R, Altimir S, Bayes-Genis A.

Clin Chim Acta. 2013 Nov 15;426:18-24. doi: 10.1016/j.cca.2013.08.014. Epub 2013 Aug 23.

PMID:
23978483
7.

Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score.

Lupón J, Gaggin HK, de Antonio M, Domingo M, Galán A, Zamora E, Vila J, Peñafiel J, Urrutia A, Ferrer E, Vallejo N, Januzzi JL, Bayes-Genis A.

Int J Cardiol. 2015 Apr 1;184:337-43. doi: 10.1016/j.ijcard.2015.02.019. Epub 2015 Feb 17.

PMID:
25734941
8.

Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score.

Scrutinio D, Ammirati E, Guida P, Passantino A, Raimondo R, Guida V, Sarzi Braga S, Pedretti RF, Lagioia R, Frigerio M, Catanzaro R, Oliva F.

Int J Cardiol. 2013 Oct 3;168(3):2120-6. doi: 10.1016/j.ijcard.2013.01.005. Epub 2013 Feb 6.

PMID:
23395457
9.

Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial.

Gravning J, Askevold ET, Nymo SH, Ueland T, Wikstrand J, McMurray JJ, Aukrust P, Gullestad L, Kjekshus J; CORONA Study Group.

Circ Heart Fail. 2014 Jan;7(1):96-103. doi: 10.1161/CIRCHEARTFAILURE.113.000450. Epub 2013 Nov 27.

10.

Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.

von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD.

J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80. Epub 2007 Oct 29.

11.

Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure.

Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC, Pastor-Perez F, Valdés M, Januzzi JL.

Eur J Heart Fail. 2011 Jul;13(7):718-25. doi: 10.1093/eurjhf/hfr047. Epub 2011 May 6.

12.

ST2 pathogenetic profile in ambulatory heart failure patients.

Bayes-Genis A, Januzzi JL, Gaggin HK, de Antonio M, Motiwala SR, Zamora E, Galán A, Domingo M, Urrutia A, Lupón J.

J Card Fail. 2015 Apr;21(4):355-61. doi: 10.1016/j.cardfail.2014.10.014. Epub 2014 Nov 3.

PMID:
25451702
13.

Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements.

Alehagen U, Dahlström U, Rehfeld JF, Goetze JP.

Clin Chem. 2010 Nov;56(11):1718-24. doi: 10.1373/clinchem.2009.141341. Epub 2010 Sep 15.

14.

Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population.

Neeland IJ, Drazner MH, Berry JD, Ayers CR, deFilippi C, Seliger SL, Nambi V, McGuire DK, Omland T, de Lemos JA.

J Am Coll Cardiol. 2013 Jan 15;61(2):187-95. doi: 10.1016/j.jacc.2012.10.012. Epub 2012 Dec 5.

15.

A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score.

Salah K, Kok WE, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Bayes-Genis A, Verdiani V, Bettari L, Lazzarini V, Damman P, Tijssen JG, Pinto YM.

Heart. 2014 Jan;100(2):115-25. doi: 10.1136/heartjnl-2013-303632. Epub 2013 Oct 31.

16.

The ADHF/NT-proBNP risk score to predict 1-year mortality in hospitalized patients with advanced decompensated heart failure.

Scrutinio D, Ammirati E, Guida P, Passantino A, Raimondo R, Guida V, Sarzi Braga S, Canova P, Mastropasqua F, Frigerio M, Lagioia R, Oliva F.

J Heart Lung Transplant. 2014 Apr;33(4):404-11. doi: 10.1016/j.healun.2013.12.005. Epub 2013 Dec 16.

PMID:
24485712
17.

Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases.

Sirithunyanont C, Leowattana W, Sukumalchantra Y, Chaisupamonkollarp S, Watanawaroon S, Chivatanaporn B, Bhuripanyo K, Mahanonda N.

J Med Assoc Thai. 2003 May;86 Suppl 1:S87-95.

PMID:
12866774
18.

Multimarker testing with ST2 in chronic heart failure.

Bayes-Genis A, Richards AM, Maisel AS, Mueller C, Ky B.

Am J Cardiol. 2015 Apr 2;115(7 Suppl):76B-80B. doi: 10.1016/j.amjcard.2015.01.045. Epub 2015 Jan 23. Review.

PMID:
25697916
19.

Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.

Sanders-van Wijk S, Maeder MT, Nietlispach F, Rickli H, Estlinbaum W, Erne P, Rickenbacher P, Peter M, Pfisterer MP, Brunner-La Rocca HP; TIME-CHF Investigators.

Circ Heart Fail. 2014 Jan;7(1):131-9. doi: 10.1161/CIRCHEARTFAILURE.113.000527. Epub 2013 Dec 18.

20.

Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.

Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R, Pacher R.

J Am Coll Cardiol. 2008 Jul 22;52(4):266-72. doi: 10.1016/j.jacc.2008.03.050.

Supplemental Content

Support Center